Table 3.

Overview of ROCK inhibitors in clinical development.^†

ROCK inhibitors	Company	Stage of development
AR-12286	Aerie Pharmaceuticals	Phase II, current
K-115	Kowa Company, Ltd.	Phase III, anticipated
INS117548	Merck	Stalled after completion of Phase I
RKI1983/SNJ-1656/Y-39983	Novartis	Stalled after completion of Phase II
ATS907	Altheos, Inc.	Phase I/II, pending in 2011
DE-104	Santen Pharmaceuticals	Discontinued after completion of Phase I/II

^†Based on on preclinical data, Rho kinase inhibitors decrease intraocular pressure by increasing conventional outflow.